Digipath
Home > Boards > US OTC > Biotechs > NorthWest Biotherapeutics Inc. (NWBO)

Juno and Kite have near-term technologies only connected

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (5) | Next 10 | Previous | Next
flipper44 Member Profile
Member Level 
Followed By 80
Posts 15,743
Boards Moderated 0
Alias Born 11/14/13
160x600 placeholder
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 1/8/2019 6:04:56 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/20/2018 4:18:14 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/11/2018 4:17:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/28/2018 5:28:53 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/23/2018 1:44:13 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/16/2018 5:38:07 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 11/15/2018 3:15:58 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/13/2018 4:49:26 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2018 4:24:26 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/14/2018 4:52:44 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/28/2018 5:23:29 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/28/2018 4:12:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/18/2018 5:16:53 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/1/2018 4:34:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/31/2018 5:01:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/31/2018 7:03:23 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/21/2018 4:44:29 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/16/2018 5:06:32 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 5/16/2018 4:42:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2018 5:26:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/2/2018 3:52:43 PM
Traders News Source Issues Research Reports on ANDI, FUSZ, RNVA and NWBO InvestorsHub NewsWire - 4/19/2018 8:00:00 AM
Annual Report (10-k) Edgar (US Regulatory) - 4/17/2018 5:11:43 PM
Revised Proxy Soliciting Materials (definitive) (defr14a) Edgar (US Regulatory) - 4/12/2018 5:26:20 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/9/2018 4:15:48 PM
flipper44 Member Level  Wednesday, 12/05/18 11:41:17 AM
Re: Basin Street Blues post# 202203
Post # of 209723 
Juno and Kite have near-term technologies only connected to 10% of the cancer market. They also dilute each other. Make that 5%. They work on leukemia and lymphoma. They do this by going after antigen(s) that make up both healthy and cancerous cells. They kill all healthy B-cells in the body. I can't impress on people enough how this is not the way it works with solid cancer. One poster here thinks Car-Ts can work on solid tumors, but they have not come close to approval. They can't attack solid tumors the same way they attack lymphoma and leukemia or they would always kill the patient. Instead, just like peptide vaccines or restricted DCVaccines, they are trying to find the right antigens and neoantigens to attack and only kill cancer cells. Just like Celldex and Immunocellular, they have not found the right cocktail of antigen(s) and neoantigen(s).

DCVax, on the other hand, has a product that can target 90% to 100% of the cancer market without artificially selecting things like killing all healthy B-cells in the body to win. Essentially, 1st and second generation Car-T's are being asked to do things the body would never do because of nature's evolutionary safety defaults. DCVax instead works within the evolutionary safety defaults.

Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (5) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist